The standard of care for patients who suffer from non-organ confined prostate cancer (CaP)
is androgen deprivation therapy (ADT). ADT exploits the reliance of CaP cells on androgen …

Androgens and the androgen receptor (AR) play crucial roles in the biology of normal and
diseased prostate tissue, including prostate cancer (PCa). This dependence is evidenced by …

Prostate cancer (PCa) progression relies on androgen receptor (AR) action. Preventing AR's
ligand-activation is the frontline treatment for metastatic PCa. Androgen deprivation therapy …

Despite aggressive treatment for localized cancer, prostate cancer (PC) remains a leading
cause of cancer-related death for American men due to a subset of patients progressing to …

Androgen receptor (AR) signaling is necessary for the development of prostate cancer.
Androgen-deprivation therapy (ADT) for prostate cancer was described over 50 years ago …

The categorization of prostate cancers that are progressing after castration as 'hormone-
refractory'evolved from the clinical observation that surgical or medical castration (ie …

Traditional endocrine therapy for prostate cancer (PCa) has been directed at suppression of
the androgen receptor (AR) signaling axis since Huggins et al. discovered that …

Patients with localized prostate cancer (PCa) have several therapeutic options with good
prognosis. However, survival of patients with high-risk, advanced PCa is significantly less …

OBJECTIVE Knowledge of the molecular and cellular changes that occur during the
transition of hormone‐naïve to castration‐resistant prostate cancer (CRPC) is increasing …

Background Prostate cancer (CaP) is the second leading cause of cancer death in American
men. Androgen deprivation therapy is initially effective in CaP treatment, but CaP recurs …